stockrow
Friday 6 November 2026
Export TARS’s income statement to Excel — free account
Tarsus Pharmaceuticals, Inc.
TARS Healthcare Biotechnology
Tarsus Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $451.4 million, up 146.7% from fiscal 2024.
- Revenue
- +63.9%
- EPS
- −4,699.1%
- Free cash flow
- −144.1%
- Total debt
- +0.90%
Quarter to September 2026, against a year earlier
68.81
1.29
+1.91%
Follow TARS
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
7.58 | 5.63 | 4.50 | 5.35 | |
P/FCF ratio |
0.00 | 0.00 | 58.11 | 155.67 | |
P/Operating CF |
176.99 | (122.24) | 44.61 | (607.99) | |
P/B ratio |
9.96 | 8.64 | 7.88 | 35.08 | |
Price to Tangible BV |
10.18 | 8.82 | 8.04 | 41.76 | |
EV/Sales |
6.81 | 5.04 | 3.88 | 5.00 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(247.04) | (163.95) | 31.75 | 68.39 | |
EV/FCF |
(98.24) | (66.54) | 50.09 | 145.58 | |
Quick Ratio |
3.72 | 3.53 | 3.12 | 1.81 | |
Current Ratio |
3.85 | 3.74 | 3.20 | 1.96 | |
Net Debt/EBITDA |
41.60 | 49.59 | 19.33 | 0.36 | |
Debt/Assets |
12.89% | 12.49% | 11.91% | 14.43% | |
Debt/Equity |
0.21 | 0.21 | 0.21 | 0.70 | |
Asset Turnover |
0.96 | 0.99 | 1.10 | 1.31 | |
Operating CF/Net income |
(2.31) | 3.54 | (3.30) | 0.01 | |
Capex/Depreciation |
19.50 | 23.00 | (10.07) | (1.61) | |
Interest Coverage |
(3.60) | (2.88) | (9.23) | (303.02) | |
Research and Development Expense of Revenue |
11.89% | 13.79% | 17.83% | 22.71% | |
Selling, General and Administrative Expense of Revenue |
86.16% | 84.19% | 86.65% | 86.36% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.03 | |
Share Based Compensation of Revenue |
9.44% | 7.38% | 7.64% | 13.99% | |
Graham Net Nets |
0.09 | 0.10 | 0.11 | 0.01 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.98%) | (1.63%) | (1.73%) | (19.32%) | |
Free Cash Flow Yield |
(0.92%) | (1.35%) | 1.72% | 0.64% | |
Revenue per Share |
3.63 | 3.77 | 4.01 | 4.19 | |
Operating CF per Share |
0.46 | (0.57) | 1.41 | (0.13) | |
Capex per Share |
(0.15) | (0.14) | (0.09) | (0.03) | |
Free Cash Flow per Share |
0.31 | (0.71) | 1.32 | (0.16) | |
Cash per Share |
10.00 | 9.05 | 10.36 | 6.67 | |
Shareholders Equity per Share |
8.22 | 8.12 | 7.99 | 2.24 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.22 | 8.12 | 7.99 | 2.24 | |
Free Cash Flow |
12.97 | (30.47) | 57.15 | (7.21) | |
Working Capital |
387.09 | 393.72 | 386.24 | 218.30 | |
Capital Expenditures |
(6.36) | (5.82) | (4.07) | (1.21) | |
Net Current Asset Value |
304.05 | 305.05 | 297.58 | 43.95 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.04 | 0.04 | 0.02 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
67.58 | 90.68 | 79.27 | 88.22 | |
Average Payables |
12.90 | 50.25 | 59.39 | 69.10 | |
Average Inventory |
3.50 | 3.64 | 4.13 | 4.50 | |
Average Assets |
469.57 | 540.94 | 553.07 | 520.03 | |
Average Common Equity |
283.98 | 345.70 | 339.67 | 219.56 |
Columns are period end dates · fundamentals updated 5 Nov 2026